Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024
This study underscores the need of pharmacovigilance in recognizing and comprehending drug-induced herpes zoster. Additional research is required to validate these findings and to design strategies for risk management and reduction to enhance treatment outcomes in patients.
Authors
- Jiali Xia (ORCID: https://orcid.org/0009-0008-9755-0186)
- Jun Li (ORCID: https://orcid.org/0000-0002-1171-7141)
- Hongyu Zhu (ORCID: https://orcid.org/0009-0003-7023-2835)
- Jing Zhang (ORCID: https://orcid.org/0009-0009-0274-7443)
Institutions
- Xuzhou Medical College (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-26
- DOI
- https://doi.org/10.3389/fphar.2025.1565480
- Citations
- 1
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.35